Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection

Exclusion Criteria

• •1. Patients with ASA IV-V
• •2. Contraindication for MRI (see 5.4.3)
• •3. Underlying chronic liver disease such as severe fibrosis or liver cirrhosis
• •4. Need for procedures additive to partial liver resection
• •5. Participation in other liver related trials
• •6. BMI \> 40
• •7. Previous liver transplantation or porto-systemic shunt
• •8. Concomitant acute infectious diseases
• •9. Renal insufficiency
• •10. Hypersensitivity to Rifaximin
• •11. Concomitant HIPEC (hypertherme intraperitoneale chemoperfusion) treatment
• •12. ALPPS (associating liver partition and portal vein ligation for staged hepatectomy)
• •13. Pregnant females as determined by positive \[serum or urine\] hCG (human chorionic gonadotropin) test at Screening or prior to dosing. Participants of child-bearing age should use adequate contraception as defined in the study protocol.
• •14. Lactating females
• •15. The subject has a history of any other illness, which, in the opinion of the investigator, might pose an unacceptable risk by administering study medication.
• •16. The subject received an investigational drug within 30 days prior to inclusion into this study
• •17. The subject has any current or past medical condition and/or required medication to treat a condition that could affect the evaluation of the study
• •18. The subject is unwilling or unable to follow the procedures outlined in the protocol
• •19. The subject is mentally or legally incapacitated